GBS Inc. Reports Second Quarter 2022 Financial Results and R

- Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant FundingAward from Australian Government -

Related Keywords

Australia , California , United States , Australian , American , Spiro Sakiris , Tim Mccarthy , Steven Boyages , Linkedin , Twitter , Company Contact , Nasdaq , Key Development , Clinical Development Plan , Research Future Fund , Research Commercialization Initiative , Lifesci Advisors , Regulatory Affairs , Drug Administration , Researcha Study , Researchb Study , Gbs Inc , Exchange Commission , Biosensor Algorithm Development , Securities Exchange , Peninsula Medical Center , University Of Newcastle , Grant Fundingaward , Australian Government , Cash Equivalents , Marketable Securities , Provides Estimated Runway , Webcast Today , Chief Executive Officer , Medical Research Commercialization Initiative , Early Stage Translation , Commercialization Support , Medical Research Future Fund , Asian Pacific , Quality Assurance , Life Science Biosensor Diagnostics , Breakthrough Device , Mills Peninsula Medical Center , Glucose Tolerance Testing , Clinical Plan , Targeted Milestones , Calendar Year , Saliva Glucose Biosensor , Manufacturing Setup Completed , Clinical Milestone Targets Correlate , Preliminary Biosensor , North American , Webcast Registration Link , Biosensor Platform , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Managing Director Lifesci Advisors , Chief Financial Officer , Money , Ational ,